Palladyne AI

Phase A — Understand the business

Company Overview

What it is, in plain terms. Palladyne AI Corp. (Nasdaq: PDYN; Salt Lake City, UT) is the company formerly known as Sarcos Technology and Robotics — renamed March 2024 "to reflect the Company's transition from a hardware-focused company to an AI software-focused company". Sarcos itself reached the public market via a 2021 de-SPAC with Rotor Acquisition Corp. So this is a thrice-reinvented entity: decades-old Sarcos exoskeleton/robotics hardware → SPAC'd → pivoted to AI software → and, as of late 2025, pivoting again into a vertically integrated defense contractor.

Core offering (the story they sell). "Embodied AI" — full-stack, closed-loop autonomy software designed to run on the edge (no cloud, no LLM, "hundreds of parameters" not billions), hardware-agnostic, across cobots, UAVs, UGVs, ROVs. Three software products:

• Palladyne IQ — industrial/commercial; makes cobots "poly-functional," learns a task in ~1-5 demonstrations.
• Palladyne SwarmOS — defense; lets one operator command a swarm of heterogeneous drones in contested, comms-degraded environments.
• Palladyne Pilot — a reduced-cost SwarmOS derivative for public-safety/commercial.

What it actually is now. Two markets per the 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. — (1) Defense & Public Safety, (2) Commercial & Industrial — but the November 2025 acquisitions tilted the actual revenue base hard toward defense hardware/services: GuideTech (avionics + UAV engineering, maker of the Gremlin-X strike drone, formerly "Banshee"), and Warnke Precision Machining + MKR Fabricators (machine shops). Management's own framing: positioning as "a mid-tier U.S. technology prime defense contractor" delivering "cost-effective lethality" and "low-cost, intelligent and collaborative attritable weapons".

Customers / contract structure. Government contracts (Army, Air Force Research Lab) — milestone/cost-plus product-development contracts plus newly-acquired commercial machining/avionics revenue. Contracts are lumpy and funding-gated: services revenue "fluctuates due to the timing of new contracts signed and the completion of existing contracts". Extreme customer concentration: one/two customers = 73% of FY2025 revenue (Customer A alone $3.852M); five customers = 78% of accounts receivable. The contract base is small enough that one program ending swings the whole P&L.

Plainest possible summary: a perennial-loss SPAC alumnus that has never commercialized a product at scale — its own risk factors concede "we were unsuccessful in our efforts to commercialize our legacy hardware" — now buying defense machine shops to manufacture Israeli loitering munitions under license, while its flagship AI software ships to a single pilot customer.

Supply Chain

Map: upstream inputs → Palladyne → end customer. Note: supply-chain.md commercial layer was referenced in context but does not exist on disk — this lens is filing- + web-grounded.

• Compute / silicon (upstream): SwarmOS/IQ run "on the edge" on third-party compute hardware shipped with the software; the 10-K flags dependence on "single, sole or limited source suppliers" for hardware components, a named risk. Edge inference chips (NVIDIA Jetson-class or equivalent) are the implicit silicon dependency — not disclosed by name.
• Avionics / airframes (now in-house): via GuideTech — Gremlin-X (Group 2 strike UAV) engineering + avionics.
• Precision components (now in-house): Warnke Precision Machining + MKR Fabricators — machining/fabrication for defense + industrial customers. Vertical integration is the explicit rationale ("U.S.-based stand-alone or vertically integrated solutions").
• Munition IP (licensed-in — the key new dependency): Israel Aerospace Industries (IAI) — exclusive U.S. rights to manufacture/market HARPY, HAROP, Mini-HARPY loitering munitions; IAI "will license related IP and may provide key subsystems and engineering support". This is a single-source chokepoint by design — the loitering-munition business is IAI's IP; Palladyne is the U.S. assembly/marketing arm.
• End customers: U.S. DoD / "Department of War" (Army, AFRL), defense primes (as a sub), and the lone commercial robotics pilot.

Chokepoints / single-source dependencies: (1) IAI for the entire loitering-munition product line — no IAI, no munitions business. (2) U.S. government appropriations — virtually the whole demand side. (3) undisclosed edge-compute supplier(s) for the AI hardware. The chain is short and brittle: a licensor, a customer (Uncle Sam), and a chip vendor.

Competitive Advantages (moats)

The claimed moat — edge-native, data-efficient autonomy (no cloud/LLM dependency, learns from a handful of demos). Plausible as a technical differentiator; unproven as a durable economic moat — there is essentially no revenue to demonstrate switching costs, network effects, or pricing power. Patents exist (SwarmOS is "patented" per the AFRL release), so there is some IP estate, but the 10-K leans on "open source" software and lists IP-protection risk as a named factor.

Bargaining power — weak in both directions. Over suppliers: it has just licensed-in its flagship weapon from IAI and pays a "market-rate royalty" with IAI free to go non-exclusive at term-end — that is licensee economics, not owner economics. Over customers: a sub-scale microcap selling to the U.S. government and to primes has minimal pricing leverage; backlog is $17.3M.

Brand / perceived value: the "Palladyne/Sarcos" brand carries a negative legacy (a multi-decade hardware company that never commercialized, a 1-for-6 reverse splitReverse stock splitMerging several shares into one to lift the share price. It changes nothing about what the company is worth, and is usually done to keep a listing or to prepare a larger raise., two Nasdaq minimum-bid violations). The new defense brand is being built on board credibility — Admiral Eric T. Olson (Ret.) and Lt. Gen. Stephen Twitty (Ret.) — which is real signaling but not a moat.

Verdict on moat: thin. The genuine edge (compute-light embodied autonomy) is early and unmonetized; the defense pivot's "moat" is an exclusive license that is contractually temporary and a board Rolodex. No durable moat established.

Segments

our figures is EMPTY — segment numbers read directly from filings.

FY2025 revenue by line:

Q1 2026 revenue by line — the tell:

The single most important fact in this dossier: the headline "+107% revenue growth" is entirely acquired. Strip the November-2025 acquisitions and the organic / core business (product-development contract revenue) collapsed 96% YoY to $67K. The company is buying a top line. The AI software that is the entire investment thesis is, on a revenue basis, going backwards toward zero. Geography: essentially 100% U.S.; all long-lived assets in the U.S..

---

Phase B — Measure performance

Earnings Result (latest print — Q1 2026, reported 2026-05-05)

unless noted.

• Revenue $3.538M, +107% YoY — but see Lens 4: 100% of the growth is acquired; organic collapsed.
• Total opex $15.457M (+79% YoY) — cost of revenue $2.473M (+601%, now carrying machine-shop COGS), R&D $3.905M (+36%), G&A $6.877M (+64%), S&M $1.847M (+52%), intangible amort $0.355M.
• Loss from operations −$11.919M (vs −$6.931M Q1-25) — operating loss widened 72% even as revenue doubled. Acquiring low-margin manufacturing revenue degraded the loss profile.
• Net loss −$12.608M ( −$0.28 basic). The prior-year "net income" of $22.759M was a non-cash warrant gain ($29.2M); this year the warrant line flipped to a −$1.046M loss. Warrant marks make GAAP net income meaningless here — watch operating loss only.
• Consensus: EPS −$0.23 reported vs −$0.18 expected = a miss.
• Balance sheet / liquidity: cash + marketable securities $43.7M (down from $47.1M at YE25); accumulated deficit −$493.4M; working capital $43.9M; backlog $17.3M ($17.0M funded), total estimated contract value $23.4M.
• Cash burn: operating cash used −$10.239M in Q1 alone (vs −$7.516M Q1-25). At that pace, $43.7M ≈ ~4 quarters of runway before another raise.
• Market reaction: premarket −7.8% to ~$6.01, then closed up ~+7.5% — i.e. a volatile, sentiment-driven whipsaw.
• Unusual vs own history: the company guided UP full-year 2026 revenue to $24–27M (357–415% YoY) — a number that only makes sense as a defense-manufacturing forecast (Gremlin-X + IAI munitions assembly + GuideTech/Warnke/MKR run-rate), NOT AI-software SaaS. The "operating inflection" they tout is a hardware/services roll-up inflection.

Earnings Calls (sentiment trend)

transcripts/ is EMPTY on disk; this is web-grounded. Tone arc across the recent communications:

• Jan 2026 (guidance raise): "Signals operating inflection" — bullish, repositioning around the acquisitions and a $24–27M number.
• Q1 2026 call (May): management leaned on "107% revenue growth," "backlog +26%," and the IQ 2.0 commercial launch; analysts/press flagged "rising losses" and "gross margin compression". The market's read was skeptical (premarket sell-off).
• June 2026: a barrage of defense-contract press (Army SwarmOS/Gremlin-X, AFRL HANGTIME, IAI partnership) — the narrative has fully shifted to defense momentum, away from commercial robotics.

What they started saying: "mid-tier prime defense contractor," "lethality," "loitering munitions," "vertically integrated." What they stopped emphasizing: broad commercial/industrial robotics TAM — IQ is now described as serving "defense-industrial modernization". The pivot is the message. Sentiment is promotional and catalyst-driven, riding the defense-tech bid rather than fundamentals.

Comps

Read: on FY26 guided revenue PDYN screens ~9–10× EV/Sales — not cheap, but not absurd for the defense-tech bid if the guide is real and durable. On trailing/organic economics it is uninvestable on multiples (≈46× a shrinking, sub-$6M core). The bull comp ("next AVAV/Kratos") requires believing the manufacturing roll-up scales to hundreds of millions; the bear comp is "a serial-diluting microcap chasing a hot sector." Do not anchor on the FY26 multiple without underwriting the guide — it is a freshly-assembled, unaudited-as-a-whole forecast.

Stock-Price Catalysts

throughout. 52-week range $4.14–$13.00; now ~$5.7–5.9 — i.e. down ~55% from the 52-wk high, near the lower third. Short interestShort interestHow many shares have been borrowed and sold by people betting the price falls. ~13.9% of shares (~5.81M) — heavily shorted. The tape reacts to:

• Defense contract announcements (positive spikes): Army SwarmOS + Gremlin-X (Jun 23, 2026), AFRL HANGTIME (Jan 28, 2026), IAI loitering-munition MOU (Jun 8, 2026).
• Guidance raises (positive): Jan 13, 2026 raise to $24–27M.
• Earnings losses / dilution (negative): Q1 miss and "rising losses" sell-off; recurring ATM share issuance is a persistent overhang.
• Sector beta: trades with the drone/defense-tech basket (ONDS/RCAT/AVAV/KTOS) on DoD-budget headlines.

Pattern: this is a headline/momentum stock — contract press releases and the defense-tech narrative move it far more than the (still tiny) financials. That cuts both ways: catalysts are frequent and binary, and the heavy short interest makes squeezes possible on good news.

---

Phase C — Judge people & books

Management

our figures not present; assessment from filings + web.

• CEO: Benjamin (Ben) Wolff — co-founded Sarcos (2015), CEO to 2021, Exec Chair to Jan 2023, returned as President & CEO Feb 2024 to run the AI pivot; >10 yrs with the company. Track record is genuinely two-sided: he co-founded and led Clearwire, sold to Sprint for $14B+ — a real, large outcome. But he also led Sarcos through the hardware era the company now disowns ("we were unsuccessful in commercializing our legacy hardware") and has a serial-SPAC/promotional profile (Pendrell/ICO patent-licensing vehicle 2009–14; currently also on Globalstar's board). He is the operator who presided over both the value creation and the value destruction in this lineage.
• CTO: Denis Garagić — co-founder of the AI software business, 25+ yrs AI/ML. The technical anchor.
• Board: heavyweight defense credibility — Adm. Eric T. Olson (Ret.) (ex-USSOCOM commander) and Lt. Gen. Stephen Twitty (Ret.) — consistent with the prime-contractor positioning.
• Capital allocation — the central red flag. Funded almost entirely by equity dilution: shares went 25.9M (YE23) → 33.9M (YE24) → 46.1M (YE25) → 47.2M (Q1-26) → ~46.5M+ (Feb-26), i.e. ~80% dilution in ~2 years via a Jefferies ATM program (sold $18M + $30M + part of a $50M tranche), warrant exercises, and 2.67M shares issued for the Nov-25 acquisitions. ROE/ROIC are meaningless (chronic operating losses; accumulated deficit −$493.4M). The acquisitions were paid 70% in stock + earnouts of up to $25M — using a momentum-inflated currency to buy a top line.
• Founder vs professional manager: founder-CEO archetype with a promoter's instinct for narrative and capital markets. For this stage (pre-commercialization, sentiment-funded), that skill set raises and spends capital well — but it is not the disciplined operator profile you want underwriting durable unit economics.

Forensic Red Flags

• regulatory file.

• GAAP net income is a warrant mirage. FY2025 reported net income +$10.039M despite a −$32.404M operating loss — driven by a +$37.740M non-cash warrant fair-value gain + a $2.538M tax benefit. FY2024 was the mirror: −$72.617M net loss including a −$46.935M warrant loss. Any headline P/E or "profitability" on this name is meaningless — always read operating loss + operating cash burnCash burnHow much more cash goes out than comes in, per period. The clock on a company with no profits.. (Q1-26 net loss −$12.6M confirms the underlying picture.)
• Acquired-revenue masks organic decline (covered in Lens 4) — the most important forensic point: consolidated +107% Q1 growth hides a 96% collapse in the original software contract revenue. A reader trusting the consolidated top line is being misled by mix.
• Goodwill/intangibles risk. The Nov-25 deals: $22.6M consideration ($5.4M cash + $15.9M stock + $1.4M contingent) created $14.7M goodwill + $10.548M intangibles. 65% of the purchase price is goodwill for two small machine shops + an avionics firm — a rich price justified by "assembled workforce and synergies." Plus up to $25M of contingent earnout on revenue targets. Impairment risk if the defense roll-up underdelivers; contingent-consideration remeasurements run through G&A (already a $0.146M Q1 hit).
• Income-tax benefit of convenience. The $2.5M FY25 tax benefit arose because deferred tax liabilities from the acquisitions let them release part of a valuation allowance — a one-off, acquisition-driven, non-cash flatterer of the FY25 bottom line.
• Dilution as the operating model (Lens 9) — the structural red flag. Warrants at $69 exercise (post 1-for-6 split; deSPAC warrants $11.50/warrant → 1/6 share) are deep underwater; 20.5M deSPAC warrants expire Sept 24, 2026 likely worthless. Earnout shares: 2.34M expired (needed $90), 2.34M remain (need $120) — a marker of how far the stock has fallen from its post-SPAC highs.
• Customer concentration: 73% of revenue from 1–2 customers.
• Controls: disclosure controls deemed effective; no material weakness; no auditor changes/disagreements. Going concernGoing concernAn auditor’s formal doubt that the company can fund itself for the next year. It is a warning about survival, not about performance.: NOT flagged — management asserts ">12 months" of liquidity (true on cash, but the runway is short and dilution-dependent).

Regulatory findings (required sub-section).

• SEC Litigation Releases / AAERs: None. regulatory/regulatory-findings.md — 0 SEC findings via EDGAR EFTS (LR + AAER) for "Palladyne AI," period 2021-06-30 → 2026-06-30.
• Non-SEC enforcement (web): no material FTC/DOJ/FDA/CFPB action surfaced. (Caveat: a defense exporter/manufacturer takes on ITAR/export-control compliance exposure going forward via the IAI munitions line — prospective, not a current finding.)
• 10-K Item 3 (Legal Proceedings): "We are not currently a party to or aware of any proceedings that we believe will have... a material adverse effect". Note: the company has had two prior Nasdaq minimum-bid non-compliance notices (regained compliance each time) — a listing-risk history, not litigation.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-30.

---

Phase D — Project & stress-test

Forward Projection (EPS, next 3 fiscal years; FYE Dec)

Bottom-up from actuals + guidance. Outputs; no our model logged (watchlist breadth mode — base case not conviction-committed). FYE = Dec 31; projecting FY2026 / FY2027 / FY2028.

Anchors /: FY25 rev $5.246M; FY26 guidance $24–27M (midpoint $25.5M); FY25 opex $37.65M; Q1-26 opex run-rate $15.46M (×4 ≈ $62M, but Q1 carries acquisition step-up); operating loss FY25 −$32.4M; cash+sec $43.7M; ~47M shares diluting ~8–12M/yr.

The number that actually matters is not EPS — it is runway vs. the next capital raise. $43.7M cash, ~$40–45M annual operating burn before the self-funded IAI U.S. assembly-line capex. Base case: another equity raise within ~12 months is near-certain, extending the dilution machine. There is no realistic path to positive EPS inside the 3-year window without (a) the defense roll-up compounding 45%+ annually AND (b) opex discipline that the history argues against. A scoreable binary worth tracking (not logged here): "PDYN reports positive operating cash flow in any quarter through FY2028" — base rate low given the model.

Bull vs Bear

Bull case (narrative). Palladyne is a cheap call option on two of the hottest secular bids at once — embodied AI and defense autonomy/attritable drones — wrapped in a sub-$300M shell. The June 2026 flurry is real: U.S. Army contracts for SwarmOS + Gremlin-X, AFRL HANGTIME (extending swarm autonomy to space), and a 10-year exclusive license to manufacture IAI's combat-proven HARPY/HAROP loitering munitions for the U.S. — a credible path to nine-figure defense revenue if even one program scales. The board (Olson, Twitty) opens prime/DoD doors. FY26 guidance of $24–27M is a 4–5× step-up; on that number the EV/Sales (~9–10×) is ordinary for the group. Heavy short interest (~14%) + a steady stream of contract catalysts = squeeze fuel. If the "next AeroVironment/Kratos" framing sticks, the re-rate is large.

Bear case (what permanently impairs it). (1) The core thesis product doesn't sell — organic software revenue fell 96% to $67K; the "growth" is bought machine-shop and avionics revenue at 65%-goodwill prices. (2) The model is dilution — ~80% share growth in two years, ~4 quarters of runway, a self-funded munitions assembly line to build, and an ATM still running. Every catalyst is monetized into the equity, capping upside. (3) Licensee, not owner — the munitions IP is IAI's, exclusivity is temporary, and the U.S. attritable-munitions market is crowding fast (AeroVironment Switchblade, dozens of Replicator entrants). Pre-mortem (18 months out, thesis broke): the Army contracts stayed at study/test dollars (BAA, not programs of record), the IAI assembly line ate cash and slipped, the IQ commercial pilot didn't expand past one robot, the company raised equity twice more at lower prices, and it screens as a perennial sub-scale diluter — back near the $4 low. Are multiples too high? On organic economics, yes (≈46× a shrinking core); on the guide, only-if-you-believe-it. Contrarian view the market is refusing to see: the bull narrative quietly swapped the product — investors think they own an embodied-AI software compounder; they actually own a sub-scale defense-manufacturing licensee funded by perpetual share issuance. The AI is the marketing layer on a roll-up.

Devil's Advocate (short-seller)

I am short. Here is the kill-shot case:

• Revenue is a magic trick. Take out two machine shops and an avionics firm bought 6 weeks before year-end and the actual business — product-development contracts that fund the AI software — fell 96% YoY to $67K. They are buying a top line with stock to mask that the thing they want you to value is decelerating to zero.
• GAAP "profit" is fake. FY25 "net income +$10M" is a non-cash warrant mark on a −$32M operating loss. Any bull citing profitability is either fooled or selling.
• Concentration + government dependence. 73% of revenue from 1–2 customers; demand is U.S. appropriations. A single contract non-renewal or a CR/budget fight guts the P&L.
• The IAI deal is weaker than the headline. It's an MOU, not a contract; Palladyne must build a U.S. assembly line at its own expense, pay royalties, and IAI can go non-exclusive at term. That's a cash-consuming licensee arrangement dressed as a moat. The U.S. loitering-munition field (Switchblade, Replicator) is brutally competitive.
• Management = serial dilution. ~80% share growth in two years; the same CEO who "was unsuccessful in commercializing our legacy hardware". Incentive to keep the story (and the multiple) hot so the ATM keeps funding the burn.
• What must hold for today's ~$282M cap: that FY26 $24–27M is real and compounds 45%+ for years, that munitions/Gremlin-X convert from test dollars to programs of record, and that they fund the assembly-line capex without crushing dilution. If FY26 revenue disappoints by 20–30% (say $18–20M, mostly low-margin machining), the defense-tech premium evaporates and it re-rates toward cash + a modest manufacturing multiple — plausibly back to the $4 handle (−30%+).
• Single scenario that permanently impairs: Army programs stay at BAA/study scale, IAI line slips/over-costs, commercial IQ never expands past one robot — the company becomes a chronically-diluting sub-$50M-revenue defense subcontractor with no software economics. Plausibility: moderate-to-high, because it is the current trajectory minus the press releases.

Management Questions (ordered by information value)

1. Strip out the GuideTech/Warnke/MKR acquisitions: what was organic revenue in FY2025 and Q1 2026, and why did product-development contract revenue fall 96% YoY? (Goes to whether there's a real AI business at all.)
2. Of the $24–27M FY2026 guidance, how much is acquired manufacturing/avionics vs. AI software (IQ/SwarmOS/Pilot) licensing, and what is the gross margin of each?
3. What is the expected total capex and timeline to stand up the U.S. IAI loitering-munition assembly line, and how is it funded — equity, debt, or operating cash?
4. The Army SwarmOS/Gremlin-X awards — are these BAA/study/test dollars or programs of record, and what is the dollar value and conversion path to production?
5. At current burn (~$10M/quarter) plus assembly-line capex, when do you next need to raise capital, and is the Jefferies ATM still your primary funding tool?
6. You've diluted shareholders ~80% in two years. What is the plan to fund the business without continuous equity issuance, and what would change it?
7. The IAI agreement is an MOU with temporary exclusivity — what are the binding milestones, royalty rate, and the conditions under which IAI can go non-exclusive?
8. Commercial IQ 2.0 is deployed to one customer / one robot. What is the realistic pipeline, and what's the expand rate you're underwriting for the commercial segment?
9. 65% of the Nov-2025 purchase price was goodwill, with up to $25M of earnouts. What revenue targets trigger the earnouts, and what is your impairment-test sensitivity?
10. How do you compete against AeroVironment (Switchblade) and the Replicator entrants in attritable munitions as a sub-scale licensee?
11. Customer concentration is ~73% from 1–2 customers. What is the de-concentration plan, and what happens if Customer A's program isn't renewed?
12. What is the SwarmOS IP position (patents, trade secrets) versus the autonomy stacks at Anduril, Shield AI, and primes — why can't they replicate the edge-native approach?
13. What are the ITAR/export-control and foreign-IP (IAI) compliance risks of the munitions business, and how are they resourced?
14. CEO Wolff led the legacy Sarcos hardware effort the company now disowns. What is structurally different this time that makes the commercialization succeed?
15. What specific, measurable milestones in the next 12 months should investors hold you accountable to — and which one would you stake the thesis on?

---